{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 236,
  "pageCount": 415,
  "prevPage": 235,
  "nextPage": 237,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/236",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-236",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Drug is counterintuitive as it causes hyperglycemia; \"value is minimal compared to what you're risking\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2aa-8bc85a26a929",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Drug is counterintuitive as it causes hyperglycemia; \"value is minimal compared to what you're risking\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13e9b767-ea0e-43f4-9ea5-7644ae908086",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "quote",
      "text": "\"I think fundamentally, if the goal is to reduce obesity and obesity and obesity-related disease... The main side effects for this drug are hypertrichosis, peripheral edema, and hyperglycemia. If you're creating hyperglycemia by giving the drug then, really, what is the benefit...\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0905d675-2914-4076-9ce2-77ec01327790",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"I think fundamentally, if the goal is to reduce obesity and obesity-related disease, which is why hyperphagia is the primary focus of all these programs, even though it is a really multifactorial disease that affects a multitude of symptoms. The main side effects for this drug are hypertrichosis, peripheral edema, and hyperglycemia. If you're creating hyperglycemia by giving the drug then, really, what is the benefit if the long-term goal of reducing obesity is to prevent obesity complications like diabetes, hypertension, and cardiovascular disease. But if you're causing hyperglycemia, to me, that is the salient point. I do think if there are patients with extreme hyperphagia, there may be physicians who are willing to take that risk and put them on this drug. But I think there's so much variability within hyperphagia itself that, unless a patient has an extreme level of hyperphagia that is not under control through any other means, yeah, I think the value is minimal compared to what you're risking.\" — Ex-Soleno employee #2, key role in clinical trial program",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2aa-8edf877a9380",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bfc3b4-a09e-4008-9168-7e7dafeae20b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The ex-employee stated that Vykat causes hyperglycemia/diabetes and other severe adverse effects, defeating its entire purpose in Prader-Willi where the goal is to reduce obesity-related complications by managing hyperphagia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02ff9058-23c2-4bbe-8e4c-c0ba627e4f2e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "ed27cbf7-ee37-4290-b406-e13aa479df34",
      "evidence": "Uses expert testimony to highlight a fundamental contradiction in the drug's clinical purpose.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}